The first TKI, imatinib (a BCR–ABL TKI), was approved by the United States Food and Drug Administration (US FDA) in May 2001 for the treatment of chronic myeloid leukemia (CML). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.